NeuroEm Therapeutics said today it launched a clinical trial testing the effect of transcranial electromagnetic treatments on patients with Alzheimer’s disease.
The 2-month, phase I clinical trial aims to examine the use of NeuroEm Therapeutics’ electromagnetic technology’s ability to prevent and reverse memory loss related to Alzheimers.
Phoenix, Ariz.-based NeuroEm’s TEMT technology uses interdigitated electric and magnetic waves that penetrate the brain to provide disease intervention, the company said, and the trial will be the 1st clinical trial examining long-term electromagnetic treatment to the entire brain.
The company’s NeuroEm 1000 Head device is designed to be used by the patient’s caregiver at home, worn twice daily for 1-hour treatments, the company said.
“We are very pleased to have two of the country’s most notable and trusted Alzheimer’s research institutes performing this first-of-its-kind clinical trial. Although the Phase I trial is primarily to investigate safety of the TEMT head device, a number of measures have been included in the trial’s design that could provide evidence of therapeutic efficacy,” prez & CEO Dr. Gary Arendash said in a press release.
The company said it hopes to complete the trial some time in Spring with results released shortly after.
The post NeuroEm launches study examining transcranial stim in treating Alzheimer’s appeared first on MassDevice.
from MassDevice http://ift.tt/2gPpGzB
Cap comentari:
Publica un comentari a l'entrada